Cadrofloxacin

Drug Profile

Cadrofloxacin

Alternative Names: CS 940

Latest Information Update: 26 Jun 2007

Price : $50

At a glance

  • Originator Sankyo; Ube Industries
  • Developer Sankyo
  • Class Antibacterials; Quinolones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 20 Jun 1996 An animal study has been added to the Bacterial infections pharmacodynamics section
  • 24 Mar 1995 Phase-II clinical trials for Bacterial infections in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top